Predictions

CENTCOM will NOT conduct publicly reported kinetic strikes on Iranian military targets in the 48-hour period August 24-25, 2026

Trump declared deal imminent; negotiations actively resuming Aug 24 — strong political incentive for restraint during active talks. However ceasefire formally expired Aug 17 and CENTCOM has conducted 13+ consecutive nights of strikes; operational posture may not align with diplomatic pace. Oil-gas|immediate calibration +17pp applied to base of 51%; final 0.68 reflects elevated restraint probability during active deal window but non-trivial strike risk from ongoing Phase 2 dynamics.

Freeport LNG feedgas receipts reach at least 2.5 Bcfd at least once during Aug 18-25 2026

All 3 Freeport LNG trains are back online and ramping, but scheduled maintenance runs through late August. Feedgas was ~1.0 Bcfd baseline during maintenance; NGI reports feedgas noms rebounding. No new unexpected outage (hyp_a6cf566ad403). Feed gas supply to Gulf Coast terminals has been uninterrupted (hyp_91c2f00b8348, win_rate 68%). 2.5 Bcfd requires near-full ramp-up before maintenance window closes — possible but unlikely until late August.

Novo Nordisk Q1 2026 Wegovy (semaglutide injection 2.4mg obesity) net revenues will exceed 2.2B when reported May 6, 2026

Wegovy has been growing strongly but faces oral GLP-1 competition now (Foundayo launched April 1, oral Wegovy launched January 2026). Q4 2025 Wegovy revenues were approximately 2.1-2.3B. Novo Nordisk postponed its price increase to August 31, indicating competitive pressure. Oral Wegovy cannibalizes injection market. Growth trajectory should continue in Q1 but at a decelerating rate. 2.2B is achievable but not certain given competitive dynamics.

Novo Nordisk will raise 2026 full-year Wegovy sales guidance above prior outlook when reporting Q1 2026 results on May 6, 2026

Novo faces competitive pressure from Foundayo (launched April 1) and its own oral Wegovy launch. Goldman projects Lilly capturing 60% oral GLP-1 share by 2030 vs Novo 21%. Novo postponed April 15 price increase - a defensive sign. But oral Wegovy is creating net new demand. Evidence of market expansion vs cannibalization will determine if Novo raises guidance. Genuine coin-flip given competing dynamics; slight lean toward maintaining rather than raising.

Novo Nordisk Q1 2026 total reported revenue beats analyst consensus estimate (reported May 6, 2026)

Novo guided DKK 235-250B for 2026. Q1 = Jan-March, before Foundayo April 1 launch. Ozempic and Wegovy demand remained strong in Q1. Novo has been a consistent beater. However, payers/PBMs may have adjusted formulary positioning for Foundayo ahead of its launch, creating channel inventory dynamics. Some uncertainty around Ozempic biosimilar entrants in non-US markets. Calibrating at 55%.

Novo Nordisk Q1 2026 Ozempic (semaglutide SC, diabetes) global net sales exceed DKK 32B on May 6, 2026 earnings

Ozempic quarterly global net sales were ~DKK 35-37B in H2 2025. Q1 2026: US payer resets create seasonal pressure. Foundayo competition is for oral GLP-1 market; injectable Ozempic remains differentiated. DKK 32B floor is achievable with modest year-over-year growth. Competition from Zepbound/Mounjaro continues but Ozempic market share stable. 0.63 probability.

Novo Nordisk Q1 2026 total revenue will show year-over-year growth of at least 10% when reported May 6, 2026

Ozempic (semaglutide GLP-1 injectable) and Wegovy (obesity) continue to dominate global market. Q1 2025 Novo revenue was DKK 65.4B. 10% growth implies ~DKK 72B. Foundayo (Lilly) launched April 1 but too early to impact Q1. Competition from oral GLP-1 mostly impacts guidance, not Q1 actuals. Strong demand trajectory supports 10%+ growth.

Novo Nordisk Q1 2026 revenue will beat consensus estimates on May 6 2026

Ozempic and Wegovy remain dominant GLP-1 market leaders. Foundayo (Lilly orforglipron) launched April 1 - too early for material Q1 revenue impact. Novo postponed April 15 price increase to August 31 (competitive response). Novo guided strong 2026 but faces intensifying competition. Risk: Foundayo uptake faster than expected, inventory buildbacks, US pricing pressure. Moderate 58% probability.

Merck-Terns Pharmaceuticals acquisition tender offer completes/closes by May 6, 2026

Tender offer expires May 4. Terns focuses on NASH/liver disease with THR-beta agonist which has no Merck portfolio overlap. No significant antitrust risk expected given niche indication. Board unanimously approved. M&A base rate for announced strategic deals ~90-95%. Small deal size (~B range) reduces financing concerns. Cornelius base rate analysis supports ~85-90%.

Novo Nordisk Q1 2026 total revenues exceed DKK 78B on May 6, 2026 earnings

Novo Q4 2025 was ~DKK 87B; Q1 typically 5-8% lower due to payer reset seasonality in US. DKK 78B represents ~10% sequential decline from Q4, achievable with mid-single digit year-over-year growth. Foundayo competition started April 1 - zero Q1 2026 impact. Ozempic/Wegovy demand remains strong. Risk: Foundayo narrative could spook market, but revenue is unaffected in Q1. 0.62 probability.

Merck-Terns Pharmaceuticals tender offer closes successfully (>50% tendered) by May 6, 2026

Merck-Terns at /share, tender expires May 4. Terns lead asset TERN-601 (GLP-1/metabolic, in development). Small deal (~B range given share count). Board approved. Standard HSR clearance. No antitrust concerns (Merck has no competing metabolic programs). Premium over last trading price typically 40-100% for clinical-stage targets. High probability of routine close. Slight uncertainty on exact tender threshold timing.

Novo Nordisk Q1 2026 net revenue shows at least 5% year-over-year growth when reported May 6, 2026

Novo guided oral Wegovy price delay to August 31 (holding at 49/mo). Foundayo (Lilly) launched April 1 - minimal Q1 2026 impact (only weeks of competition). Ozempic and Wegovy still dominant in GLP-1 market. Novo had 25%+ revenue growth in recent quarters. The 5% threshold is deliberately low to test directional call. Goldman/analysts project Novo retaining significant GLP-1 market share in 2026. Even with competitive pressure, 5% YoY revenue growth in Q1 2026 is very achievable given strong bas

Novo Nordisk Q1 2026 net sales growth exceeds analyst consensus when reported May 6, 2026

Novo postponed April 15 price increase to August 31 (competitive response to Foundayo at 49/mo). Q1 largely pre-Foundayo competition (Foundayo launched April 1, minimal impact). Wegovy/Ozempic demand elevated. Novo has history of beating consensus but faces intensifying GLP-1 oral competition and pricing pressure. Goldman Sachs forecast Lilly 60% vs Novo 21% oral GLP-1 share by 2030 signals market share anxiety. Pharma Brier 0.184. Net 58% probability of beat given mixed competitive signals.

Novo Nordisk does NOT further cut FY2026 revenue guidance (maintains -5% to -13% range or improves) at Q1 2026 earnings on May 6, 2026

NVO currently guides -5% to -13% adjusted sales growth for FY2026. Q1 2026 results (Jan-Mar) predate Foundayo April 1 launch so Q1 data alone shouldn't force a cut. However, Goldman estimated Lilly wins 60% oral GLP-1 share vs Novo 21% by 2030. Novo announced 2027 price cuts. Risk of proactive guidance cut to manage expectations. Stock at multi-year lows suggests market already pricing deterioration. 52% probability NVO holds guidance, 48% cuts again.

Novo Nordisk Q1 2026 total DKK revenue shows negative year-over-year growth when reported May 6, 2026

NVO guided -5% to -13% adjusted sales growth for full year 2026. Q1 2026 is Jan-Mar, which predates Foundayo (April 1 launch). However, oral Wegovy at $149/mo launch signaling was announced in advance of April and may have already been dampening demand. Q1 2025 was strong (pre-CagriSema miss). Analysts have updated estimates, but the guided range implies negative growth. Stock at multi-year lows suggests market expects deterioration. 0.55 probability of negative year-over-year revenue growth Q1

Leqembi IQLIK SC starting dose receives full (traditional) approval rather than accelerated approval, if FDA acts by August 24, 2026 PDUFA

FDA explicitly stated no approvability concerns with IQLIK as starting dose - CMC extension is manufacturing/quality only. IV Leqembi received traditional approval in July 2023. SC maintenance formulation already approved August 2025. sBLA for SC starting dose is a formulation extension with PK bridging showing equivalent exposure. Traditional approval pathway is appropriate for supplemental formulation changes with equivalent PK. FDA domain adjustment applied. Base 0.72 (prior approval P) * 0.9

Leqembi IQLIK (lecanemab SC starting dose) will receive FDA approval by the August 24, 2026 PDUFA date

FDA explicitly stated no concerns about approvability — CMC-only amendment extending review to Aug 24. SC maintenance dose (360mg) already approved August 2025. Phase 3 OLE sub-studies confirmed equivalent PK exposure to IV. Supplemental BLA with FDA 'no approvability concern' statement = 80%+ historical approval rate. CMC review is the only remaining gating factor. Calibration +14pp applied from base ~0.68.

At least one new oncology biotech M&A deal (>B) announced within 2 weeks after AACR 2026 concludes (by May 6, 2026)

AACR (April 17-22) is a catalyst for oncology M&A as acquirers see updated clinical data. 2026 has been a strong M&A year (~2B in Q1). Patent cliff urgency continues for large pharma. However, AACR data for specific assets like zoldonrasib and daraxonrasib is Phase 1/2 - too early for typical acquisition target. The M&A pipeline is conference-agnostic with its own timeline. Base rate: ~2-3 major oncology deals per month in 2026. Probability of at least one >B announcement in the 2 weeks post-AAC

At least one oncology biotech M&A deal will be announced within two weeks of AACR 2026 close (by May 6, 2026)

AACR conferences historically catalyze M&A activity in oncology — companies see data and move quickly on acquisition targets. Story_016 explicitly notes AACR April 17-22 may catalyze oncology M&A. With ~2B+ in Q1 M&A already done, large pharma has demonstrated appetite and financial capacity. Hot areas: KRAS inhibitors, ADCs, CCR8. 60% probability of at least one deal in 2-week post-conference window.

Neurocrine-Soleno acquisition receives HSR antitrust clearance (no second request) within 30 days of April 6, 2026 announcement (by May 6, 2026)

VYKAT XR for Prader-Willi is a rare disease drug with no competitive overlap with Neurocrine's portfolio. Low antitrust risk; Cornelius KB: rare disease M&A completion ~85-90%. HSR second request typically issued for deals with market overlap. 30-day initial HSR review period standard. 72% probability of early termination/clearance within first 30 days.